Affinity Asset Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Affinity Asset Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$599K	Hold	145,000	–	–	0.03%	102
2025 Q4	$580K	Buy	+145,000	New	+$527K	0.03%	92
2021 Q2	–	Sell	-2,500	Closed	-$646K	–	81
2021 Q1	$646K	Buy	+2,500	New	+$657K	0.22%	59

Other funds holding XFOR

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Affinity Asset Advisors's XFOR Position: Q1 2026 in Review

Affinity Asset Advisors held its X4 Pharmaceuticals (XFOR) position steady in Q1 2026 at 145,000 shares worth $599K. The position accounts for 0.03% of the portfolio, ranked #102.

Affinity Asset Advisors first reported a position in XFOR in Q1 2021 and has held it in 3 quarters since. The position peaked at $646K in Q1 2021. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

Affinity Asset Advisors held 145,000 shares of X4 Pharmaceuticals worth $599K as of Q1 2026.
Affinity Asset Advisors left its X4 Pharmaceuticals share count unchanged in Q1 2026.
X4 Pharmaceuticals made up 0.03% of Affinity Asset Advisors's portfolio in Q1 2026, its #102 holding.
Affinity Asset Advisors first reported a position in X4 Pharmaceuticals in Q1 2021 and has held it in 3 quarters since.
Affinity Asset Advisors's X4 Pharmaceuticals position peaked at $646K in Q1 2021.
84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.